The results of the international CAPTURE study with adult T2DM patients (n = 9823) clearly indicated a gap between clinical benefit evidence and real-world practice; GLP-1-RAs and/or SGLT-2 inhibitors were used only a small portion (21.9%) of patients, which was similar in participants with and without cardiovascular diseases (21.5% and 22.2%, respectively) [42]. Here, GLP1R is linked to type 2 diabetes mellitus.